Northland Securities Forecasts Weaker Earnings for Indivior

Indivior PLC (NASDAQ:INDV) – Northland Securities reduced their Q4 2026 earnings estimates for shares of Indivior in a note issued to investors on Thursday, February 26th. Northland Securities analyst C. Byrnes now forecasts that the company will earn $0.70 per share for the quarter, down from their prior forecast of $0.71. The consensus estimate for Indivior’s current full-year earnings is $1.22 per share.

INDV has been the topic of a number of other reports. Weiss Ratings reiterated a “hold (c)” rating on shares of Indivior in a report on Wednesday, January 28th. Zacks Research lowered shares of Indivior from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 13th. Morgan Stanley reiterated an “overweight” rating and set a $36.00 price objective on shares of Indivior in a report on Wednesday, December 3rd. Finally, HC Wainwright boosted their target price on shares of Indivior from $35.00 to $48.00 and gave the stock a “buy” rating in a research report on Monday, January 12th. Five investment analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat, Indivior presently has an average rating of “Moderate Buy” and a consensus price target of $39.33.

Indivior Stock Performance

Shares of Indivior stock opened at $31.98 on Monday. The stock has a market capitalization of $4.00 billion, a PE ratio of 19.50 and a beta of 0.83. Indivior has a 52 week low of $8.64 and a 52 week high of $38.00. The stock has a 50 day moving average price of $34.46 and a two-hundred day moving average price of $30.15.

Indivior (NASDAQ:INDV) last issued its earnings results on Thursday, February 26th. The company reported $0.82 EPS for the quarter, beating analysts’ consensus estimates of $0.65 by $0.17. Indivior had a negative return on equity of 148.76% and a net margin of 16.85%.The business had revenue of $358.00 million during the quarter, compared to analyst estimates of $305.62 million.

Institutional Investors Weigh In On Indivior

Several large investors have recently made changes to their positions in the business. VIRGINIA RETIREMENT SYSTEMS ET Al increased its holdings in Indivior by 3.4% during the 4th quarter. VIRGINIA RETIREMENT SYSTEMS ET Al now owns 21,200 shares of the company’s stock worth $761,000 after acquiring an additional 700 shares during the period. Blue Trust Inc. grew its position in shares of Indivior by 17.8% during the 4th quarter. Blue Trust Inc. now owns 4,859 shares of the company’s stock valued at $176,000 after purchasing an additional 733 shares in the last quarter. Harbor Capital Advisors Inc. increased its holdings in shares of Indivior by 309.9% in the fourth quarter. Harbor Capital Advisors Inc. now owns 1,033 shares of the company’s stock worth $37,000 after purchasing an additional 781 shares during the period. Salomon & Ludwin LLC purchased a new stake in shares of Indivior in the fourth quarter worth $30,000. Finally, GAMMA Investing LLC boosted its stake in Indivior by 544.6% during the fourth quarter. GAMMA Investing LLC now owns 1,199 shares of the company’s stock valued at $43,000 after buying an additional 1,013 shares during the period. 60.33% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Indivior

In other Indivior news, Director Barbara Ryan purchased 775 shares of the firm’s stock in a transaction that occurred on Monday, January 5th. The stock was bought at an average cost of $35.39 per share, with a total value of $27,427.25. Following the completion of the transaction, the director owned 1,963 shares of the company’s stock, valued at $69,470.57. The trade was a 65.24% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director David E. Wheadon purchased 1,771 shares of the company’s stock in a transaction that occurred on Monday, January 5th. The shares were acquired at an average price of $35.39 per share, for a total transaction of $62,675.69. Following the completion of the acquisition, the director directly owned 14,395 shares of the company’s stock, valued at $509,439.05. This trade represents a 14.03% increase in their position. The SEC filing for this purchase provides additional information. Insiders bought 4,871 shares of company stock valued at $172,385 in the last quarter.

About Indivior

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.